BioLineRX
BLRX
31 hedge funds and large institutions have $1.34M invested in BioLineRX in 2024 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 4 closing their positions.
933% more call options, than puts
Call options by funds: $31K | Put options by funds: $3K
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
0% more funds holding
Funds holding: 31 → 31 (0)
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
44% less capital invested
Capital invested by funds: $2.42M → $1.34M (-$1.08M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$88.6K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$30.3K |
| 3 |
PAM
PVG Asset Management
Golden,
Colorado
|
+$23.1K |
| 4 |
AI
Atria Investments
Charlotte,
North Carolina
|
+$20K |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
+$17.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$746K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$68.8K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$26.3K |
| 4 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
-$23.4K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$14.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BBA
26
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
| $5.09K | +$9.09K | +331 | New |
|
|
GWM
27
Geneos Wealth Management
Englewood,
Colorado
| $2.43K | -$23.4K | -850 | -88% |
|
|
NA
28
NewEdge Advisors
New Orleans,
Louisiana
| $2.31K | – | – | – |
|
29
Osaic Holdings
Scottsdale,
Arizona
| $646 | -$137 | -5 | -14% |
|
30
UBS Group
Zurich,
Switzerland
| $527 | -$330 | -12 | -32% |
|
|
TCM
31
Tradewinds Capital Management
Bellingham,
Washington
| $108 | – | – | – |
|
32
JP Morgan Chase
New York
| $1 | -$1.04K | -38 | Closed |
|
|
TSS
33
Two Sigma Securities
New York
| – | -$26.3K | -1,156 | Closed |
|
|
GI
34
GAMMA Investing
Foster City,
California
| – | -$124 | -5 | Closed |
|
BLRX Hedge Fund Activity: Q3 2024 in Review
31 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q3 2024, worth a combined $1.34M — down 44% from $2.42M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new BLRX positions and 4 closed out — a net gain of 1 holder — while 8 added to existing stakes and 9 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $88.6K. The largest seller was Alyeska Investment Group, cutting an estimated $746K.
- 31 institutional investors held BioLineRX (BLRX) as of Q3 2024, unchanged from Q2 2024.
- Funds reported $1.34M of BioLineRX stock for Q3 2024, down 44% quarter-over-quarter.
- 5 funds opened new BioLineRX positions in Q3 2024 and 4 closed out, a net change of +1 holder.
- The largest BioLineRX buyer in Q3 2024 was Morgan Stanley, an estimated $88.6K added.
- The largest BioLineRX seller in Q3 2024 was Alyeska Investment Group, an estimated $746K sold.
Based on aggregated 13F filings for Q3 2024.